Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Bryan S Walsh"'
Publikováno v:
Journal of Clinical Oncology. 40:1102-1110
PURPOSE Generic competition can be delayed if brand-name manufacturers obtain additional patents on supplemental uses. The US Food and Drug Administration allows generic drug manufacturers to market versions with skinny labels that exclude patent-pro
Recent Orange and Purple Book legislation suggests a need to bridge drug and biologic patent regimes
Publikováno v:
Nature Biotechnology. 40:167-169
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
Antiretroviral (ARV) medications to treat HIV are a major contributor to Medicaid prescription drug spending. Despite having been used for over 2 decades, the first generic ARVs only recently became available, and many newer versions continue to be s
Publikováno v:
JAMA. 326(14)
Autor:
Aaron S. Kesselheim, Bryan S Walsh
Publikováno v:
The American journal of managed care. 27(8)
In response to brand-name drug manufacturers developing co-pay assistance programs to help patients pay high out-of-pocket costs for expensive brand-name drugs, insurers have developed co-pay accumulator adjustment programs (CAAPs) that exclude payme
Publikováno v:
JAMA Intern Med
This cohort study assessed the frequency of approvals of first generic drugs with skinny labels in the US.
Publikováno v:
JAMA Internal Medicine. 182:245
Autor:
Carrier, Michael A.1, Tu, S. Sean2
Publikováno v:
Texas Intellectual Property Law Journal. Jan2024, Vol. 32 Issue 2, p79-110. 32p.
Autor:
Lorey, Maya1
Publikováno v:
University of Chicago Law Review. Sep2023, Vol. 90 Issue 5, p1517-1563. 47p.
Autor:
TU, S. SEAN1, DUAN, CHARLES2
Publikováno v:
Journal of Intellectual Property & Entertainment Law. Fall2022, Vol. 12 Issue 1, p1-51. 51p.